US 10434096
Tyrosine kinase inhibitors
granted A61KA61K31/4545A61K31/519
Quick answer
US patent 10434096 (Tyrosine kinase inhibitors) held by Rigel Pharmaceuticals, Inc. expires Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Rigel Pharmaceuticals, Inc.
- Grant date
- Tue Oct 08 2019 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Oct 03 2039 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 6
- CPC classes
- A61K, A61K31/4545, A61K31/519, A61P, A61P35/00